Deep Dive: Market Access 2024

Against a backdrop of escalating healthcare costs and resource constraints, ensuring patient access to vital medicines is an uphill battle for pharma companies. From navigating complex regulatory landscapes and reimbursement policies to overcoming market exclusivity hurdles, successfully overcoming the myriad obstacles encountered on the path to market and beyond is both a science and an art.

But, as this issue’s contributors illustrate, the industry does not shy away from a challenge.

With multiple big-name biologics nearing the precipice of a steep patent cliff, pioneers in biosimilars are primed to take a slice of the market, bringing hope for more affordable medication options in the US. But, patients may have to wait to access those competitor products. In this issue, delve into the high-stakes patent games drugmakers play to extend exclusivity windows.

Elsewhere in this issue, Alexion discusses the urgent need for accelerated access programmes for rare disease treatments, Putnam (part of Inizio Advisory) explores common pain points and best practices in integrating market access considerations into investment decisions, and in a double feature, pharmaphorum’s Jonah Comstock and Nicole Raleigh dive into the world of AMR.

Plus, we find out what is driving ongoing ADHD drug shortages and experts on the floor at Reuters Pharma US share their views on improving access to affordable therapeutics.

For all this and more, read on.

Eloise McLennan – editor, Deep Dive

For the best page-viewing experience, make sure you have your browser at full-screen size. Use the left/right arrow buttons to scroll through the pages or click on the menu icon bottom centre to navigate. You can also share the articles on social media by clicking the icon bottom left at the base of the main navigation or at the end of each article.

Oncology 2024

  • Top trends and talking points from ASCO 2024


Catch up on recent issues:

Research & Development – February 2024

Digital Health – November 2023

Patients & Partnerships – October 2023

Communications & Commercialisation – September 2023


Your name

Your e-mail

Name receiver

E-mail address receiver

Your message